BURKITT LYMPHOMA

This study tests a new drug called zilovertamab vedotin in children and young adults (up to age 30) whose blood cancers or solid tumors have come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the cancer. About 90 participants…

This early-phase study tests whether a patient's own immune cells, modified to target a protein called CD19 on cancer cells, can safely treat several types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. About 36 adults with relapsed or refrac…

This early-phase study is testing a new treatment for adults with certain types of blood cancer (B-cell lymphomas) that have returned or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (LV20.19 CAR…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with B-cell lymphoma that has returned or not improved after prior treatment. The goal is to see if this drug mix is safe and can control the c…

This study tests a new drug called pidnarulex (CX-5461) in 50 people with aggressive B-cell lymphomas that have MYC gene changes. The goal is to find a safe dose and see if it can shrink tumors. Participants have already tried other treatments and have limited options.

This study tests whether adding specially prepared donor immune cells can help children recover from stem cell transplants faster and avoid dangerous infections. Participants are children under 25 with high-risk blood cancers who have already received a transplant. The goal is to…

This study tests a mix of six drugs (ViPOR-P) in people with B-cell lymphoma that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 55 adults will receive up to six 21-day cycles of oral pills and IV infusio…

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This study tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have certain types of non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of treatment. T…

This study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 adults with untreated or minimally treated disease will receive the combination. The goal is to improve c…

This study is for children with Burkitt's lymphoma, a type of cancer. It aims to improve how doctors evaluate the disease stage and treatment response, especially for early-stage and advanced-stage cases. By closely monitoring 1,000 children, researchers hope to adjust treatments…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …

This study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. T…